<p>Sarepta Therapeutics announced that another patient receiving its gene therapy for rare muscle diseases has died from acute liver failure. The company stated that this death occurred in a patient who received the one-time treatment drug Elevidys, and three months ago, a teenage boy died after receiving the treatment. Both cases involved patients with Duchenne muscular dystrophy who were unable to walk. The company has suspended a clinical trial, stopped shipping the drug to patients who cannot walk, and is considering strengthening the immunosuppressive regimen for these patients</p>

SRPT

<p>Sarepta Therapeutics reported a second death case related to its gene therapy, with a patient receiving Elevidys treatment dying from acute liver failure. Three months ago, another teenage boy also died from the same treatment. Both cases involved patients with Duchenne muscular dystrophy who were unable to walk. The company has suspended the relevant clinical trials and stopped providing the drug to such patients, and is considering strengthening the immunosuppressive regimen</p>

Sarepta reports a second death case related to its gene therapy